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S U M M A R Y
Globally 10.4 million new tuberculosis (TB) incident cases were estimated to have occurred in 2015, of
which 3% were reported in the World Health Organization European Region. Importantly, about 25% of
the global multidrug-resistant TB (MDR-TB) cases are reported in the European Region, representing one
of the greatest challenges to TB control; these are reported particularly in the countries of the Former
Soviet Union. Over a quarter of TB cases in the European Union and European Economic Area (EU/EEA)
are reported among foreign-born individuals. In line with the recent increase of migration ﬂows towards
Europe, TB among migrant populations is also on the rise, emphasizing the need for a better
understanding of the TB trends at the regional and sub-regional levels, and of the existing policies on
migrants and refugees. The present article is aimed at describing the policies and practices of European
countries with a low and intermediate TB incidence with regard to the detection and management of TB
and latent TB infection (LTBI) among refugees in Europe.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction: tuberculosis (TB) and migration
Out of the 10.4 million newly diagnosed tuberculosis (TB) cases
estimated to have occurred globally in 2015, 3% were reported
from the World Health Organization (WHO) European Region
countries (11% being HIV-infected).1,2 According to the latest
surveillance data, 25% of global multidrug-resistant TB (MDR-TB)
cases are estimated to occur in the WHO European Region; they
represent one of the top priorities for TB control (and eventually
elimination), particularly in Eastern Europe.3,4
Over a quarter of TB cases in the European Union and European
Economic Area (EU/EEA) are reported among foreign-born
individuals. Four countries (France, Germany, Spain, and the UK)
account for 74.9% of all cases reported among migrants.2 The
recent increase of migration ﬂows towards Europe further
emphasizes the need for a better understanding of the TB trends* Corresponding author.
E-mail address: giovannibattista.migliori@fsm.it (G.B. Migliori).
Please cite this article in press as: D’Ambrosio L, et al. European policie
Dis (2017), http://dx.doi.org/10.1016/j.ijid.2016.11.002
http://dx.doi.org/10.1016/j.ijid.2016.11.002
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).at regional and sub-regional levels, and of the existing policies on
migrants and refugees. Discrimination, hostility, and economic
adversity (here deﬁned in agreement with the 1951 ‘Convention
and Protocol relating to the status of Refugees’ http://www.unhcr.
org/3b66c2aa10.html) are factors afﬂicting the lives of many
migrants and refugees across Europe.1–4Several factors (including
free movement within the EU and the Newly Independent States,
for seasonal labour) have contributed to increase population
mobility within and towards Europe,5–7 which poses new
challenges for TB control and elimination. New efforts are therefore
needed to make quality prevention, diagnosis, and treatment of
both TB and latent TB infection (LTBI) possible.6,8
Better coordination is necessary to ensure that individual
human rights (independent of the legal or residential status of
the subject) are preserved and that public health pre-requisites
to control and ultimately eliminate TB are met. This includes
proper prevention, diagnosis, and treatment of both MDR and
extensively drug-resistant (XDR)-TB.9–11 In the interests of both
the individual and the wider hosting community, unrestricted
free access to TB diagnosis and treatment (with a guarantee ofs in the management of tuberculosis among migrants. Int J Infect
ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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ensured to undocumented migrants as well, as recommended by
the WHO.12–16
2. TB and refugees
Over one million refugees and migrants entered Europe in 2015,
while this was ‘only’ 216 000 in 2014.5,17 Between January 1 and
September 30, 2016 an estimated 302 335 new migrants reached
the Europe Region, with 3498 deaths/missing ofﬁcially reported.
Interestingly, over 60% of those landing in Europe after crossing the
Mediterranean Sea were born in 10 countries, as summarized in
Figure 1.17 As of today, the top four countries of origin for asylum
seekers are the Syrian Arab Republic (28% of total arrivals),
Afghanistan (14%), Iraq (9%), and Nigeria (8%).17
The aim of the present article is to describe the policies and
practices of European countries with a low and intermediate TB
incidence with regard to the detection and management of TB and
LTBI among refugees in Europe.6,18
3. The European survey on policies
The survey was performed between October 2015 and February
2016, and was coordinated by the TB Advocacy ad-hoc Working
Group of the European Respiratory Society (ERS), in collaboration
with the WHO Regional Ofﬁce for Europe and the European Region
of the International Union Against Tuberculosis and Lung Disease
(The Union).19 The survey included multiple choice and open-
ended questions concerning screening and management of TB and
LTBI among refugees in Europe. It was completed by theFigure 1. Recent evidence on migrant movements to Europe (available at http://d
Please cite this article in press as: D’Ambrosio L, et al. European polici
Dis (2017), http://dx.doi.org/10.1016/j.ijid.2016.11.002coordinators of national TB programmes of all EU/EEA countries
of the WHO European Region, plus six additional EU candidate
countries (Albania, Bosnia and Herzegovina, the former Yugoslav
Republic of Macedonia, Montenegro, Serbia, and Turkey) and
Switzerland.19
4. Results
All countries except two (36/38, 94.7%) answered the question-
naire. A summary of the core results is presented in Table 1.
Thirty-one countries (86.1%) reported that screening is
performed for active TB and 19 for LTBI. Eight countries only
(22.2%) collected data on LTBI treatment outcomes. Interestingly,
about half of the countries not yet screening are developing TB and
LTBI screening plans. National guidelines in force imply a legal
obligation to screen for TB and/or LTBI in almost 60% of the
surveyed countries (21/36).
Country representatives reported details on how screening
practices are organized. Active TB screening is essentially based on
diagnostic algorithms including different combinations of symp-
tom-based questionnaires, bacteriological examinations, and chest
radiography. LTBI screening is conducted through different
combinations of interferon-gamma release assays (IGRAs) and/
or the tuberculin skin test (TST).
Conﬁrming previous ﬁndings,11 LTBI screening was found to be
performed by TST only in 22.2% of the countries (8/36), by TST plus
IGRA in 30.5% of the countries, and by TST plus IGRA only in
selected cases in 11% of the countries. Screening practices were
found to be organized differently based on the setting- or country-
speciﬁc organization of health services. In the majority of countriesata.unhcr.org/mediterranean/regional.php, last accessed September 30, 2016).
es in the management of tuberculosis among migrants. Int J Infect
Table 1
Summary of the core ﬁndings of the recently published survey on European policies and practices among refugeesa
Active TB LTBI
Screening
Yes: 31/36 (86.1%)
No: 2/36 (5.2%)
Not systematic: 3/36 (8.3%)
Screening
Yes: 19/36 (52.7%)
No: 9/36 (25%)
Not systematic: 8/36 (22.2%)
Symptom-based questionnaires:
Systematic: 20/36 (55.5%)
Not systematic: 1/36 (2.7%)
Bacteriology
Systematic: 9/36 (25%)
For symptomatic individuals only: 9/36 (25%)
Chest radiography
Systematic: 25/36 (69.4%)
Not systematic: 2/36 (5.5%)
Other proceduresb: 1/36 (2.7%)
Not systematic screening: 5/36 (13.9%)c
TST: 19/36 (52.7%)
TST only: 8/36 (22.2%)
TST plus IGRA: 11/36 (30.5%)
Not systematic TST plus IGRA: 4/36 (11.1%)
Not applicable: 13/36 (36.1%)
Procedures if diagnosis of active TB
No refusal of asylum: 34/36 (94.4%)
Obligation to undergo treatment: 24/36 (66.6%)
Other: 10/36 (27.7%)
Not applicable: 2/36 (5.5%)
Procedures if diagnosis of LTBI
No refusal of asylum: 20/36 (55.5%)
Obligation to undergo preventive therapy: 8/36 (22.2%)
Other: 18/36 (50%)
Not applicable: 8/36 (22.2%)
Data collection to assess treatment success rates
Yes: 19/36 (52.7%)
No: 10/36 (27.7%)
Not answered: 6/36 (16.6%)
Not applicable: 1/36 (2.7%)
Data collection to assess completion rates
Yes: 8/36 (22.2%)
No: 20/36 (55.5%)
Not answered: 6/36 (16.6%)
Not applicable: 2/36 (5.5%)
Screening and management according to national/
international guidelines/legislation
Yes: 27/36 (75%)
No: 3/36 (8.3%)
Not applicable: 1/36(2.7%)
Not answered: 5/36 (13.8%)
Screening and management according to national/international guidelines/legislation
Yes: 19/36 (52.7%)
No: 7/36 (19.4%)
Not applicable: 5/36 (13.8%)
Not answered: 5/36 (13.8%)
Place of screening Refugee centres only: 10/36 (27.7%)
On arrival only: 4/36 (11.1%)
Community only: 1/36 (2.7%)
National TB programme centre only: 1/36 (2.7%)
On arrival and in refugee centres: 6/36 (16.6%)
On arrival and pre-arrival: 1/36 (2.7%)
On arrival and in the community: 1/36 (2.7%)
On pre-arrival and in the community: 1/36 (2.7%)
In refugee centres and in the community: 6/36 (16.6%)
Not applicable: 5/36 (13.8%)
Legal requirement for screening Yes: 21/36 (58.3%)
No: 12/36 (33.3%)
Not applicable: 3/36 (13.8%)
Plans to implement screening for active TB/LTBI Yes: 8/17d (47%)
No: 5/17d (29.4%)
Not answered: 3/17d (17.6%)
Not applicable: 1/17d (5.9%)
Special measures to deal with undocumented migrants Yes: 22/36 (61.1%)
No: 1/36 (2.7%)
Not answered: 13/36 (36.1%)
Infection control measures for individuals with possible TB Respirators used for staff and surgical masks for individuals with possible TB or other
respiratory disease: 24/36 (66.6%)
Only respirator used for staff in contact with refugees: 1/36 (2.7%)
Other: 7/36 (19.4%)
Not answered: 4/36 (11.1%)
TB, tuberculosis; LTBI, latent tuberculosis infection; TST, tuberculin skin test; IGRA, interferon-gamma release assay.
a From Dara et al.,19 modiﬁed; 36 countries surveyed.
b Initial algorithm with tuberculin skin tests (TST) and blood examination.
c Numerator includes countries that do not systematically perform any examination.
d Denominator is the number of countries that do not (or do not systematically) screen for TB/LTBI.
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refugee centres. In 22 countries (61.1%), screening interventions
are managed through a strict collaboration between governmental
and private sector staff.
The majority of countries (75%) answered that screening
practices are consistent with both national and international
guidelines in force. The proportion decreased to 52.7% (n = 19) for
LTBI screening. Several countries reported that infection control
measures were considered suboptimal, although respirators werePlease cite this article in press as: D’Ambrosio L, et al. European policie
Dis (2017), http://dx.doi.org/10.1016/j.ijid.2016.11.002reported to be available to protect health staff to complement
administrative measures.
5. From evidence to recommendations
The results of the study are pivotal to coordinate future
initiatives in favour of an improved management of refugees in
Europe.19 The high response rate conﬁrmed that the topic is of
importance to the agenda of the different countries. The relevants in the management of tuberculosis among migrants. Int J Infect
Table 2
Summary of the recommendations of the European Respiratory Society, the World Health Organization Europe Region, and The Union Europe Region on core actions for
optimal management of tuberculosis among refugeesa
Recommendation Comments
1 Ensure adequate prevention, diagnosis, and treatment of TB and LTBI based on
the End TB Strategy
LTBI management is a core intervention to pursue TB elimination; diagnosis and
treatment of LTBI might be not feasible in all countries
2 Provide quality surveillance, monitoring, and evaluation, coupled with
operational research
Solid evidence is needed to guide public health interventions; operational
research is necessary to guide rational introduction of the diagnostics and drugs
3 Ensure timely screening for TB among refugees born in middle and high TB
incidence countries
Evidence on yield and the cost-effectiveness of screening practices is needed
4 Prevent stigmatization and stereotypes, of both TB infected people and
vulnerable groups
The recommendation aims at encouraging unrestricted access to TB services
5 Promote universal access to LTBI (in the countries where these are offered) and
TB services (prevention, diagnosis, and treatment)
Universal access includes adequate management of comorbidities
6 Ensure quality infection control in settings where refugees are hosted, screened,
and treated
The package includes protective measures for staff, as well as HIV testing and
counselling to detect HIV and TB–HIV co-infected individuals
TB, tuberculosis; LTBI, latent tuberculosis infection.
a From Dara et al.,27 modiﬁed.
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European level, of coordinating complex interventions, which
imply technical expertise, organization of different services, and
important funding, as well as delicate legal and ethical issues.
As expected, more information was available on TB than on LTBI
screening practices. Feasibility issues are clearly driving these
results. In some countries, the large numbers of arrivals and the
increased mobility make LTBI screening even more difﬁcult to
perform. Further research, providing data on the yield of different
screening practices and on their cost-effectiveness, will provide
better information to design rational and sustainable screening
plans.
A core research priority, given the increased breakdown risk
(LTBI progressing to TB disease because of the prevalent unhealthy
travel conditions), is represented by the management of LTBI.1,10,11
This intervention is, in fact, crucial if the TB elimination strategy is
taken into consideration.10,11
From the organizational point of view, inter-sectoral collabo-
ration involving governmental and private services is key to
increase the cultural sensitivity of TB services. The importance of
ensuring quality infection control measures whenever TB patients
are hosted needs also to be underlined.20 The results of this and
similar studies will support the proper implementation of the End
TB Strategy, the TB Action Plan for the WHO European Region
2016–2020,21 and the Health 2020 Policy Framework22 to address
inequity. The ﬁnal goal of these strategies is to end TB and
ultimately eliminate TB.10,11,23–25Additional evidence is obviously
necessary.26
The ERS and the WHO Regional Ofﬁce for Europe have
proactively launched a new branch of the TB Consilium (an
internet-based and cost-free platform supporting clinicians
managing difﬁcult-to-treat TB cases) to allow better cross-border
TB control among refugees and migrants. The new function is
presently live and accessible at the TB Consilium website (http://
www.tbconsilium.org). The hope is to contribute to improve
prevention, diagnostic, and treatment services for migrants and
refugees. Furthermore, the same ERS TB Advocacy ad-hoc
Committee, in collaboration with the WHO Ofﬁce for Europe
and The Union Europe Region have developed recommendations
for the better management of migrants and refugees27(Table 2).
In conclusion, the new interest raised among politicians and
policymakers on these delicate issues needs to be channelled into
concrete actions promoting unrestricted access of migrants and
refugees to TB prevention, diagnostic, and treatment services,
while ensuring that individual human rights are met and that the
community is protected from further transmission of Mycobacte-
rium tuberculosis.Please cite this article in press as: D’Ambrosio L, et al. European polici
Dis (2017), http://dx.doi.org/10.1016/j.ijid.2016.11.002Financial support: No funding was received by the authors.
Conﬂict of interest: No competing interest declared.
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